HIV

From 1996 by Mark Harrington After Berlin, no one could credibly believe that AIDS drug development was on track. Indeed, it looked likely that the various initiatives AIDS activists had worked with FDA, NIH and industry to develop were actually…

Current Issues in Research and Treatment of HIV-Associated Wasting and Malnutrition by Tim Horn & David Pieribone July 1996 From the Introduction Wasting syndrome can be a chronic and deadly manifestation of HIV. Multiple studies demonstrate that progressive weight loss…

by Mark Harrington 7 November 1995 In September, 1994, the Treatment Action Group spelled out the following conditions as necessary for our support of an accelerated NDA for an HIV protease inhibitor: Adequate and well-controlled clinical endpoints studies are well…

AIDS Research Highlights from the 35th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC) September 1995 by Mark Harrington and Michael Marco with Spencer Cox and Tim Horn From the Introduction The 35th ICAAC was a more interesting conference than…

August 1995 By Spencer Cox Edited by Mark Harrington & Bruce Schackman From the Executive Summary Over the period in which FDA has reviewed and regulated anti-HIV therapies, there has been a substantial decline in the quality and quantity of…

Current Issues in Research and Treatment of AIDS-Associated Lymphoma by Michael Marco May 1995 From the Introduction Lymphomas are not new. They pre-date AIDS for many many years. We have known for some time that organ transplant patients and others…

February 1995 By David Barr, Spencer Cox, Gregg Gonsalves, Mark Harrington, Derek Link, Michael Ravitch & Theo Smart Edited by Mark Harrington for the National Task Force on AIDS Drug Development From the Introduction The development of protease inhibitors offers…